-

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

The audio webcast replay will be available approximately 48 hours after the webcast.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

Industry:

Johnson & Johnson

NYSE:JNJ
Release Versions
English

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson to Host Enterprise Business Review

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of the Innovative Medicine and MedTech businesses, highlight how their pipelines are shaping the future of healthcare, and discuss the Company’s long-term strategy for delivering the next wave of growth and shareholder value. The Enterprise Business Review will...

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare...

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to r...
Back to Newsroom